446 related articles for article (PubMed ID: 31279870)
1. Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease.
Li K; Friedman JR; Chan D; Pollack P; Yang F; Jacobstein D; Brodmerkel C; Gasink C; Feagan BG; Sandborn WJ; Rutgeerts P; De Hertogh G
Gastroenterology; 2019 Oct; 157(4):1019-1031.e7. PubMed ID: 31279870
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
Rutgeerts P; Gasink C; Chan D; Lang Y; Pollack P; Colombel JF; Wolf DC; Jacobstein D; Johanns J; Szapary P; Adedokun OJ; Feagan BG; Sandborn WJ
Gastroenterology; 2018 Oct; 155(4):1045-1058. PubMed ID: 29909019
[TBL] [Abstract][Full Text] [Related]
3. Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease.
Danese S; Sandborn WJ; Colombel JF; Vermeire S; Glover SC; Rimola J; Siegelman J; Jones S; Bornstein JD; Feagan BG
Gastroenterology; 2019 Oct; 157(4):1007-1018.e7. PubMed ID: 31279871
[TBL] [Abstract][Full Text] [Related]
4. Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease.
Löwenberg M; Vermeire S; Mostafavi N; Hoentjen F; Franchimont D; Bossuyt P; Hindryckx P; Rispens T; de Vries A; van der Woude CJ; Berends S; Ambarus CA; Mathot R; Clasquin E; Baert F; D'Haens G
Gastroenterology; 2019 Oct; 157(4):997-1006.e6. PubMed ID: 31175865
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease.
Adedokun OJ; Xu Z; Gasink C; Jacobstein D; Szapary P; Johanns J; Gao LL; Davis HM; Hanauer SB; Feagan BG; Ghosh S; Sandborn WJ
Gastroenterology; 2018 May; 154(6):1660-1671. PubMed ID: 29409871
[TBL] [Abstract][Full Text] [Related]
6. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Feagan BG; Sandborn WJ; Gasink C; Jacobstein D; Lang Y; Friedman JR; Blank MA; Johanns J; Gao LL; Miao Y; Adedokun OJ; Sands BE; Hanauer SB; Vermeire S; Targan S; Ghosh S; de Villiers WJ; Colombel JF; Tulassay Z; Seidler U; Salzberg BA; Desreumaux P; Lee SD; Loftus EV; Dieleman LA; Katz S; Rutgeerts P;
N Engl J Med; 2016 Nov; 375(20):1946-1960. PubMed ID: 27959607
[TBL] [Abstract][Full Text] [Related]
7. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease.
Geboes K; Rutgeerts P; Opdenakker G; Olson A; Patel K; Wagner CL; Marano CW
Curr Med Res Opin; 2005 Nov; 21(11):1741-54. PubMed ID: 16307694
[TBL] [Abstract][Full Text] [Related]
8. Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis.
Li K; Marano C; Zhang H; Yang F; Sandborn WJ; Sands BE; Feagan BG; Rubin DT; Peyrin-Biroulet L; Friedman JR; De Hertogh G
Gastroenterology; 2020 Dec; 159(6):2052-2064. PubMed ID: 32853634
[TBL] [Abstract][Full Text] [Related]
9. Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease.
Dubinsky M; Ma C; Griffith J; Crowell M; Neimark E; Kligys K; O'Connell T
Adv Ther; 2023 Sep; 40(9):3896-3911. PubMed ID: 37368103
[TBL] [Abstract][Full Text] [Related]
10. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
Sands BE; Sandborn WJ; Panaccione R; O'Brien CD; Zhang H; Johanns J; Adedokun OJ; Li K; Peyrin-Biroulet L; Van Assche G; Danese S; Targan S; Abreu MT; Hisamatsu T; Szapary P; Marano C;
N Engl J Med; 2019 Sep; 381(13):1201-1214. PubMed ID: 31553833
[TBL] [Abstract][Full Text] [Related]
11. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
Battat R; Kopylov U; Bessissow T; Bitton A; Cohen A; Jain A; Martel M; Seidman E; Afif W
Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1427-1434.e2. PubMed ID: 28365485
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial.
Danese S; Panaccione R; Feagan BG; Afzali A; Rubin DT; Sands BE; Reinisch W; Panés J; Sahoo A; Terry NA; Chan D; Han C; Frustaci ME; Yang Z; Sandborn WJ; Hisamatsu T; Andrews JM; D'Haens GR;
Lancet Gastroenterol Hepatol; 2024 Feb; 9(2):133-146. PubMed ID: 38104569
[TBL] [Abstract][Full Text] [Related]
13. Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
Danese S; Vermeire S; D'Haens G; Panés J; Dignass A; Magro F; Nazar M; Le Bars M; Lahaye M; Ni L; Bravata I; Lavie F; Daperno M; Lukáš M; Armuzzi A; Löwenberg M; Gaya DR; Peyrin-Biroulet L;
Lancet Gastroenterol Hepatol; 2022 Apr; 7(4):294-306. PubMed ID: 35120656
[TBL] [Abstract][Full Text] [Related]
14. The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies.
Narula N; Aruljothy A; Wong ECL; Homenauth R; Alshahrani AA; Marshall JK; Reinisch W
United European Gastroenterol J; 2021 Jun; 9(5):581-589. PubMed ID: 34077627
[TBL] [Abstract][Full Text] [Related]
15. Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates.
Verstockt B; Dreesen E; Noman M; Outtier A; Van den Berghe N; Aerden I; Compernolle G; Van Assche G; Gils A; Vermeire S; Ferrante M
J Crohns Colitis; 2019 Jul; 13(7):864-872. PubMed ID: 30715258
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.
Sandborn WJ; Rutgeerts P; Gasink C; Jacobstein D; Zou B; Johanns J; Sands BE; Hanauer SB; Targan S; Ghosh S; de Villiers WJS; Colombel JF; Feagan BG
Aliment Pharmacol Ther; 2018 Jul; 48(1):65-77. PubMed ID: 29797519
[TBL] [Abstract][Full Text] [Related]
17. Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
Sandborn WJ; Gasink C; Gao LL; Blank MA; Johanns J; Guzzo C; Sands BE; Hanauer SB; Targan S; Rutgeerts P; Ghosh S; de Villiers WJ; Panaccione R; Greenberg G; Schreiber S; Lichtiger S; Feagan BG;
N Engl J Med; 2012 Oct; 367(16):1519-28. PubMed ID: 23075178
[TBL] [Abstract][Full Text] [Related]
18. Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial.
Sandborn WJ; Rebuck R; Wang Y; Zou B; Adedokun OJ; Gasink C; Sands BE; Hanauer SB; Targan S; Ghosh S; de Villiers WJS; Colombel JF; Feagan BG; Lynch JP
Clin Gastroenterol Hepatol; 2022 Mar; 20(3):578-590.e4. PubMed ID: 33618023
[TBL] [Abstract][Full Text] [Related]
19. The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn's Disease.
Sands BE; Han C; Gasink C; Jacobstein D; Szapary P; Gao LL; Lang Y; Targan S; Sandborn WJ; Feagan BG
J Crohns Colitis; 2018 Jul; 12(8):883-895. PubMed ID: 29726939
[TBL] [Abstract][Full Text] [Related]
20. Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs.
Ghosh S; Gensler LS; Yang Z; Gasink C; Chakravarty SD; Farahi K; Ramachandran P; Ott E; Strober BE
Drug Saf; 2019 Jun; 42(6):751-768. PubMed ID: 30739254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]